

CHEEVER et al.
Application No.: 09/493,480
Page 2

PATENT

IN THE SPECIFICATION:

Please substitute the paragraphs on page 52, lines 4-10, with the following amended version:

D¹
Other preferred adjuvants include Montanide ISA 720 (Seppic, France), SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron), Detox (Corixa Corporation, Hamilton, MT), RC-529 (Corixa, USA) and Aminoalkyl glucosaminide 4-phosphates (AGPs).

In a preferred embodiment, the adjuvant is described in EP 735898B1

IN THE CLAIMS:

Please substitute claims 93 and 103 with the following amended version:

D²
93. (twice amended) An isolated nucleic acid encoding a fusion protein comprising a HER-2/neu extracellular domain fused to a HER-2/neu phosphorylation domain, wherein the nucleic acid hybridizes under stringent conditions to the complement of a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:6, and separately to the complement of a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:3, and separately to the complement of a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:4, wherein the hybridization reaction is incubated in a solution comprising 5x SSC at a temperature of 50-65°C and washed in a solution comprising 0.2x SSC and 0.1% SDS at a temperature of 65°C, and wherein the protein is capable of producing an immune response in a warm-blooded animal.

D³
103. (twice amended) An isolated nucleic acid encoding a fusion protein comprising a HER-2/neu extracellular domain fused to a fragment of the HER-2/neu phosphorylation domain, wherein the nucleic acid hybridizes under stringent conditions to the complement of a nucleic acid encoding the amino acid sequence of SEQ

CHEEVER et al.
Application No.: 09/493,480
Page 3

PATENT

D³
ID NO:7, and separately to the complement of a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:3, and separately to the complement of a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:5, wherein the hybridization reaction is incubated in a solution comprising 5x SSC at a temperature of 50-65°C and washed in a solution comprising 0.2x SSC and 0.1% SDS at a temperature of 65°C, and wherein the protein is capable of producing an immune response in a warm-blooded animal.

Please add new claims 125-130:

- D⁴
125. (new) A composition comprising the nucleic acid of claim 93 or 103, and a lipid.
126. (new) The composition of claim 98 or 108, wherein the viral vector is an adenoviral vector.
127. (new) The composition of claim 99 or 109, comprising an oil-in-water emulsion.
128. (new) The composition of claim 127, comprising tocopherol.
129. (new) The composition of claim 101 or 111, wherein the immunostimulatory substance comprises 3D-MPL, QS21, or a combination of 3D-MPL and QS21.
130. (new) The composition of claim 101 or 111, wherein the immunostimulatory substance comprises 3D-MPL and QS21 in an oil-in-water emulsion.
131. (new) The composition of claim 130, comprising tocopherol.
132. (new) The composition of claim 99 or 109, comprising a CpG-containing oligonucleotide.
-